Thomssen C - Search Results

1

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E; European School of Oncology; European Society of Medical Oncology. Cardoso F, et al. Among authors: thomssen c. Breast. 2014 Oct;23(5):489-502. doi: 10.1016/j.breast.2014.08.009. Epub 2014 Sep 20. Breast. 2014. PMID: 25244983 Free article. No abstract available.

2

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.

Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H. Schmitt M, et al. Among authors: thomssen c. Br J Cancer. 1997;76(3):306-11. doi: 10.1038/bjc.1997.383. Br J Cancer. 1997. PMID: 9252196 Free PMC article.

3

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.

Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Höfler H, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Br J Cancer. 1999 May;80(3-4):419-26. doi: 10.1038/sj.bjc.6690373. Br J Cancer. 1999. PMID: 10408848 Free PMC article.

4

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.

Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Breast Cancer Res Treat. 1999 Mar;54(2):147-57. doi: 10.1023/a:1006118828278. Breast Cancer Res Treat. 1999. PMID: 10424405

5

Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.

Prechtl A, Harbeck N, Thomssen C, Meisner C, Braun M, Untch M, Wieland M, Lisboa B, Cufer T, Graeff H, Selbmann K, Schmitt M, Jänicke F. Prechtl A, et al. Among authors: thomssen c. Int J Biol Markers. 2000 Jan-Mar;15(1):73-8. doi: 10.1177/172460080001500114. Int J Biol Markers. 2000. PMID: 10763145 Free article. Clinical Trial.

6

Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.

Harbeck N, Krüger A, Sinz S, Kates RE, Thomssen C, Schmitt M, Jänicke F. Harbeck N, et al. Among authors: thomssen c. Onkologie. 2001 Jun;24(3):238-44. doi: 10.1159/000055086. Onkologie. 2001. PMID: 11455216 Review. English, German.

7

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Among authors: thomssen c. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

8

[u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].

Harbeck N, Thomssen C. Harbeck N, et al. Among authors: thomssen c. Zentralbl Gynakol. 2003 Sep;125(9):362-7. doi: 10.1055/s-2003-43036. Zentralbl Gynakol. 2003. PMID: 14569518 German.

9

Clinical relevance of prognostic factors in axillary node-negative breast cancer.

Thomssen C, Jänicke F, Harbeck N. Thomssen C, et al. Onkologie. 2003 Oct;26(5):438-45. doi: 10.1159/000072976. Onkologie. 2003. PMID: 14605459 Review.

10

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. Among authors: thomssen c. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

331 results

Search Page